The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study.
 
Stephen Lam Chan
Consulting or Advisory Role - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis
 
Terry Cheuk-Fung Yip
Employment - Synergy Health (Hong Kong) Limited; Synergy Health (Hong Kong) Limited; Synergy Health (Hong Kong) Limited; Synergy Health (Hong Kong) Limited
 
Vincent Wai-Sun Wong
Consulting or Advisory Role - 3-V Biosciences; 3-V Biosciences; 3-V Biosciences; 3-V Biosciences; Abbvie; Abbvie; Abbvie; Abbvie; Allergan; Allergan; Allergan; Allergan; Echosens; Echosens; Echosens; Echosens; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen; Novartis; Novartis; Novartis; Novartis; Novo Nordisk; Novo Nordisk; Novo Nordisk; Novo Nordisk; Perspectum Diagnostics; Perspectum Diagnostics; Perspectum Diagnostics; Perspectum Diagnostics; Pfizer; Pfizer; Pfizer; Pfizer; Terns Pharmaceuticals; Terns Pharmaceuticals; Terns Pharmaceuticals; Terns Pharmaceuticals
Speakers' Bureau - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Echosens; Echosens; Echosens; Echosens; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Merck; Merck; Merck; Merck
Research Funding - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Anthony W.H. Chan
Honoraria - Novartis; Novartis; Novartis; Novartis
Consulting or Advisory Role - Novartis; Novartis; Novartis; Novartis
 
Cathy Ka Kiu Tong
No Relationships to Disclose
 
Yee Kit Tse
No Relationships to Disclose
 
Becky Wing-Yan Yuen
No Relationships to Disclose
 
Hester Wing-Sum Luk
No Relationships to Disclose
 
Grace Chung-Yan Lui
Consulting or Advisory Role - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Speakers' Bureau - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Merck; Merck; Merck; Merck
Research Funding - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Henry L.Y. Chan
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Aligos Therapeutics; Aligos Therapeutics; Aligos Therapeutics; Aligos Therapeutics; Altimmune; Altimmune; Altimmune; Altimmune; Aptorum; Aptorum; Aptorum; Aptorum; Arbutus Biopharma; Arbutus Biopharma; Arbutus Biopharma; Arbutus Biopharma; ContraVir; ContraVir; ContraVir; ContraVir; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GRAIL; GRAIL; GRAIL; GRAIL; Intellia Therapeutics; Intellia Therapeutics; Intellia Therapeutics; Intellia Therapeutics; Janssen; Janssen; Janssen; Janssen; Medimmune; Medimmune; Medimmune; Medimmune; Roche; Roche; Roche; Roche; Vaccitech; Vaccitech; Vaccitech; Vaccitech; VenatoRx; VenatoRx; VenatoRx; VenatoRx; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology
Speakers' Bureau - AbbVie; AbbVie; AbbVie; AbbVie; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Roche; Roche; Roche; Roche
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong; The Chinese University of Hong Kong; The Chinese University of Hong Kong; The Chinese University of Hong Kong
Leadership - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Sanomics Limited; Sanomics Limited; Sanomics Limited; Sanomics Limited
Stock and Other Ownership Interests - Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Sanomics Limited; Sanomics Limited; Sanomics Limited; Sanomics Limited
Honoraria - ACEA Biosciences; ACEA Biosciences; ACEA Biosciences; ACEA Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Fishawack Facilitate; Fishawack Facilitate; Fishawack Facilitate; Fishawack Facilitate; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Ignyta; Ignyta; Ignyta; Ignyta; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; Takeda; Takeda; Takeda; Takeda; Vertex; Vertex; Vertex; Vertex
Consulting or Advisory Role - ACEA Biosciences; ACEA Biosciences; ACEA Biosciences; ACEA Biosciences; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Cirina; Cirina; Cirina; Cirina; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; geneDecode; geneDecode; geneDecode; geneDecode; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Ignyta; Ignyta; Ignyta; Ignyta; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Oncogenex; Oncogenex; Oncogenex; Oncogenex; Pfizer; Pfizer; Pfizer; Pfizer; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; SFJ Pharmaceuticals Group; Vertex; Vertex; Vertex; Vertex
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); SFJ Pharmaceuticals Group (Inst); SFJ Pharmaceuticals Group (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst); Xcovery (Inst); Xcovery (Inst); Xcovery (Inst)
 
Grace Lai-Hung Wong
Consulting or Advisory Role - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen
Speakers' Bureau - Abbott; Abbott; Abbott; Abbott; Abbvie; Abbvie; Abbvie; Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Echosens; Echosens; Echosens; Echosens; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen; Roche; Roche; Roche; Roche